4'-氰基-4-联苯基磺酸 | 780010-15-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4'-氰基-4-联苯基磺酸
• 英文名称: 4'-cyano[1,1'-biphenyl]-4-sulfonic acid
• 英文别名: 4'-Cyano-4-biphenylsulfonic acid；4-(4-cyanophenyl)benzenesulfonic acid
• CAS: 780010-15-3
• 化学式: C₁₃H₉NO₃S
• 分子量: 259.285
• InChiKey: MTLNOSBZCGTCEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  86.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4'-氰基-4-联苯基磺酸 在 sodium hydroxide 、 三氯氧磷 作用下， 生成 4'-cyano[1,1'-biphenyl]-4-sulfonyl chloride
  参考文献：
  名称：

  11β-羟基类固醇脱氢酶的N-（吡啶-2-基）芳基磺酰胺抑制剂1：发现PF-915275

  摘要：

  N-（吡啶-2-基）芳基磺酰胺被鉴定为11β-羟基类固醇脱氢酶1（11βHSD1）的抑制剂，该酶催化糖皮质激素可的松还原为皮质醇。糖皮质激素的调节异常与糖尿病和代谢综合征的发病机理有关。在这封信中，我们介绍了使用缺失策略开发具有改进的理化性质的有效配体的初步方法。该策略允许进一步优化效能，从而导致临床候选药物PF-915275的发现。

  DOI：

  10.1016/j.bmcl.2009.05.011
• 作为产物：
  描述：

  4-氰基联苯 在 氯磺酸 作用下， 以 二氯甲烷 为溶剂， 生成 4'-氰基-4-联苯基磺酸
  参考文献：
  名称：

  11β-羟基类固醇脱氢酶的N-（吡啶-2-基）芳基磺酰胺抑制剂1：发现PF-915275

  摘要：

  N-（吡啶-2-基）芳基磺酰胺被鉴定为11β-羟基类固醇脱氢酶1（11βHSD1）的抑制剂，该酶催化糖皮质激素可的松还原为皮质醇。糖皮质激素的调节异常与糖尿病和代谢综合征的发病机理有关。在这封信中，我们介绍了使用缺失策略开发具有改进的理化性质的有效配体的初步方法。该策略允许进一步优化效能，从而导致临床候选药物PF-915275的发现。

  DOI：

  10.1016/j.bmcl.2009.05.011

文献信息

• Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
  申请人：Cheng Hengmiao

  公开号：US20050148631A1

  公开（公告）日：2005-07-07

  The present invention relates to compounds with the formula (I), or a pharmaceutically acceptable salt thereof: The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) or formula (II) and methods of treating a condition that is mediated by the modulation of 11-β-hsd-1, the method comprising administering to a mammal an effective amount of a compound of formula (I) or formula (II).

  本发明涉及具有化学式(I)或其药学上可接受的盐的化合物：该发明还涉及包含化学式(I)或化学式(II)化合物的药物组合物，以及治疗通过调节11-β-hsd-1介导的疾病的方法，该方法包括向哺乳动物施用化学式(I)或化学式(II)化合物的有效量。
• 신규한 헤테로고리 화합물
  申请人：NeoPharm Co., LTD. (주)네오팜(120000320884) Corp. No ▼ 160111-0100688BRN ▼305-81-38977

  公开号：KR101560536B1

  公开（公告）日：2015-10-16

  본 발명은 신규한 헤테로고리 화합물 또는 이들의 약학적으로 허용되는 염 및 용매화물에 관한 것으로, 이를 유효성분으로 함유하는 약학조성물 또는 화장품 조성물은 피부질환의 치료 또는 예방에 매우 유용하다.

  该发明涉及新型的杂环化合物或其药学上可接受的盐和溶剂化合物，含有其作为有效成分的药学组合物或化妆品组合物对于治疗或预防皮肤疾病非常有用。
• [EN] BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY<br/>[FR] DERIVES DE BENZENESULFONYLAMINO-PYRIDIN-2-YL ET COMPOSES APPARENTES EN TANT QU'INHIBITEURS DE LA 11-BETA-HYDROXYSTEROIDE DESHYDROGENASE TYPE 1 (11-BETA-HSD-1) POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE
  申请人：PFIZER

  公开号：WO2005060963A1

  公开（公告）日：2005-07-07

  The present invention relates to compounds with the formula (I), or a pharmaceutically acceptable satt thereof, formula (I), wherein: R' is selected from the group consisting of (C1--C6)alkyl, -(CR<3>R<4>),(C3-C12)cycloalkyl, -(CR<3>R<4>),(C6-C12)aryl, and -(CR<3>R<4>)t(410)-membered heterocyclyl; b and k are each independently selected from 1 and 2; j is selected from the group consisting of 0, 1, and 2; t, u, p, q, and v are each independently selected from the group consisting of 0, 1, 2, 3, 4, and 5; T is a (6-10)-membered heterocyclyl containing at least one nitrogen atom; R<2> is selected from the group consisting of H, (C1-C6)alkyl, -(CR<3>R)t(C3-C12)cycloalkyl, -(CR<3>R<4>)t(C6-C12)aryt, and -(CR<3>R<4>)t(410)-membered heterocyclyl; each R<3 >and R<4>.is independently selected from H and (C1-C6)alkyl, the carbon atoms of T, R', R<2>,< >R<3> and R<4> may each be optionally, substituted by I to 5 R<5> groups; Ris defined in the claims; The compounds of the present invention are 11 ß-hsd-1 inhibitors, and are therefore believed to be useful in the treatment of diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders, depression, hypertension, and metabolic diseases.

  本发明涉及具有公式(I)的化合物或其药学上可接受的盐，公式(I)中：R'从(C1-C6)烷基，-(CR<3>R<4>)，(C3-C12)环烷基，-(CR<3>R<4>)，(C6-C12)芳基和-(CR<3>R<4>)t(4-10)成员杂环基组成的群体中选择；b和k各自独立地选择为1和2；j从0、1和2的群体中选择；t、u、p、q和v各自独立地从0、1、2、3、4和5的群体中选择；T是一个至少含有一个氮原子的(6-10)成员杂环基；R<2>从H、(C1-C6)烷基，-(CR<3>R)t(C3-C12)环烷基，-(CR<3>R<4>)t(C6-C12)芳基和-(CR<3>R<4>)t(4-10)成员杂环基中选择；每个R<3>和R<4>独立地从H和(C1-C6)烷基中选择，T、R'、R<2>、R<3>和R<4>的碳原子可以选择地被1-5个R<5>基团取代；R在权利要求中定义；本发明的化合物是11ß-hsd-1抑制剂，因此被认为在糖尿病、肥胖症、青光眼、骨质疏松症、认知障碍、免疫障碍、抑郁症、高血压和代谢性疾病的治疗中有用。
• 4-AMINO-1H-PYRIMIDIN-2-ONE BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF THEIR USE
  申请人：Augeri David J.

  公开号：US20080182847A1

  公开（公告）日：2008-07-31

  4-Amino-1H-pyrimidin-2-one-based compounds, compositions comprising them, and methods of their use for the treatment, prevention and management of various diseases and disorders are disclosed. Particular compounds are of formula I:

  本发明涉及基于4-氨基-1H-嘧啶-2-酮的化合物，包括这些化合物的组合物，以及它们在治疗、预防和管理各种疾病和疾病障碍方面的使用方法。具体化合物的化学式为I:
• Methods and compositions for treating alcohol use disorders
  申请人：Sanna Pietro Paolo

  公开号：US10039772B2

  公开（公告）日：2018-08-07

  Disclosed are methods and compositions for treating alcohol dependence by administration to a patient of an inhibitor of 11β-hydroxysteroid dehydrogenases (11β-HSD) to modulate glucocorticoid effects. One such compound is the 11β-HSD inhibitor carbenoxolone (18β-glycyrrhetinic acid 3β-O-hemisuccinate), which has been extensively employed in the clinic for the treatment of gastritis and peptic ulcer. Carbenoxolone is active on both 11β-HSD1 and 2 isoforms. Here, carbenoxolone is surprisingly shown to reduce both baseline and excessive drinking in rats and mice. The carbenoxolone diastereomer 18α-glycyrrhetinic acid 3β-O-hemisuccinate (αCBX), which the applicants discovered to be selective for 11β-HSD2, was also effective in reducing alcohol drinking in mice. Thus, 11β-HSD inhibitors are a new class of candidate alcohol abuse medications and existing 11β-HSD inhibitor drugs may be re-purposed for alcohol abuse treatment.

  本发明公开了通过向患者施用 11β-羟基类固醇脱氢酶（11β-HSD）抑制剂以调节糖皮质激素作用来治疗酒精依赖症的方法和组合物。其中一种化合物是 11β-HSD 抑制剂卡本诺酮（18β-甘草次酸 3β-O-hemisuccinate ），临床上已广泛用于治疗胃炎和消化性溃疡。卡贝诺酮对 11β-HSD1 和 2 同工酶均有活性。令人惊讶的是，羧甲诺龙在大鼠和小鼠体内可减少基线饮酒量和过量饮酒量。申请人发现，羧诺龙的非对映异构体 18α-甘草次酸 3β-O-hemisuccinate (αCBX)对 11β-HSD2 具有选择性，也能有效减少小鼠的饮酒量。因此，11β-HSD 抑制剂是一类新的候选酗酒药物，现有的 11β-HSD 抑制剂药物可重新用于酗酒治疗。